FDA Approves Sulfasalazine for the Treatment of Juvenile Rheumatoid Arthritis
The Food and Drug Administration (FDA) has approved sulfasalazine (Asulfinine En-tabs®) for the treatment of children (ages 6-16) with juvenile rheumatoid arthritis (JRA). Data from a randomized, double-blind, clinical trial showed that sulfasalazine, compared to placebo, significantly reduced the severity of swollen joints, the number of active joints, the overall joint severity score, and reduced disease activity scores assessed by physicians, parents and patients.